Scholar Rock/$SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Ticker
$SRRK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
128
ISIN
US80706P1030
Website
Scholar Rock Metrics
BasicAdvanced
$3.4B
-
-$2.78
0.38
-
Price and volume
Market cap
$3.4B
Beta
0.38
52-week high
$46.98
52-week low
$6.76
Average daily volume
1.2M
Financial strength
Current ratio
10.253
Quick ratio
9.749
Long term debt to equity
18.457
Total debt to equity
20.217
Interest coverage (TTM)
-39.11%
Profitability
EBITDA (TTM)
-268.993
Management effectiveness
Return on assets (TTM)
-50.15%
Return on equity (TTM)
-106.71%
Valuation
Price to book
11.03
Price to tangible book (TTM)
11.03
Price to free cash flow (TTM)
-14.97
Free cash flow yield (TTM)
-6.68%
Free cash flow per share (TTM)
-242.62%
Growth
Earnings per share change (TTM)
21.16%
3-year earnings per share growth (CAGR)
-2.79%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Bulls say / Bears say
Scholar Rock's lead drug candidate, apitegromab, demonstrated significant improvement in motor function for spinal muscular atrophy (SMA) patients in a Phase 3 trial, leading to a 300% surge in share price. (reuters.com)
The company successfully raised $300 million through a public offering, strengthening its financial position to support the commercialization of apitegromab and advance other clinical programs. (stocktitan.net)
Analysts have raised price targets for Scholar Rock, with Truist Financial increasing its target to $45.00, reflecting confidence in the company's growth prospects. (etfdailynews.com)
Scholar Rock reported a net loss of $58.5 million in Q2 2024, an increase from $37.9 million in the same period the previous year, indicating rising operational expenses. (nasdaq.com)
The company's earnings per share (EPS) of -$0.60 missed analysts’ expectations by $0.01, suggesting potential challenges in achieving profitability. (nasdaq.com)
Despite positive trial results, the approval and commercialization of apitegromab are pending, and any regulatory delays could negatively impact the stock. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Scholar Rock News
AllArticlesVideos
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Benzinga·2 days ago
Scholar Rock Shares Jump on Positive Results from Weight Loss Trial
Market Watch·2 days ago
Scholar Rock's drug helps preserve lean mass in mid-stage trial
Reuters·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $3.4B as of June 20, 2025.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of June 20, 2025.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.